AACR Meeting Abstracts
HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH
Cancer ResearchClinical Cancer Research
Cancer Epidemiology Biomarkers & PreventionMolecular Cancer Therapeutics
Molecular Cancer ResearchCancer Prevention Research
Cancer Prevention Journals PortalCancer Reviews Online
Annual Meeting Education BookMeeting Abstracts Online
 QUICK SEARCH:   [advanced]




This Article
Services
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Raza, A.
Right arrow Articles by Galili, N.
PubMed
Right arrow Articles by Raza, A.
Right arrow Articles by Galili, N.
99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA


Phase II and III Clinical Trials 3: Blood, Lung, Brain/CNS, and Sarcoma: Poster Presentations - Proffered Abstracts


Abstract #5528

Multi-lineage response to a combination of gingerol and curcumin in low risk myelodysplastic syndromes (MDS).

Azra Raza, Portia Lagmay, Murtaza Mehdi, Muhammad Mumtaz, Richa Upadhyay, Ayesha Butt, Talaha Ali and Naomi Galili

Saint Vincent's Comprehensive Cancer Center, New York, NY, University of Massachusetts Medical Center, Worcester, MA

Management of lower risk MDS patients who are still transfusion-independent has not been extensively examined, therapy being typically withheld until patients either become transfusion-dependent or show signs of disease progression. Low intensity therapies could be tried in these patients for two potential benefits; to improve the cytopenias and to determine of intervention at this early stage could arrest and/or reverse the expansion of the abnormal clone. We combined curcumin, the major active ingredient of the spice turmeric, which interferes with a host of cell signals and has anti-cancer, anti-proliferative, anti-inflammatory, anti-angiogenic and anti-oxidant properties, with gingerol, the active constituent of ginger, which is anti-leukemic, anti-bcl-2, inhibits EGF-induced transformation and prevents the development of colon cancer cells, to treat 9 patients with low or Int-1 risk MDS on a clinical trial. Curcumin was administered in an incremental dosing schedule starting with 2.0 Gm in 4 divided doses/day, increasing to 8 Gm/day and Gingerol 350mg bid increasing to 1.4Gm/day (supplied by Sami Labs, NJ). The high dose of ginger-curcumin has been very well tolerated with little or no side effects. The preliminary results have been very encouraging. Patients have been followed for 4-18 months and included 7 males and 2 females with 6 RA, 2 RARS, and 1 unclassified. One patient has been lost to follow-up, 2 are too early for response evaluation (done every six months), but of the 6 remaining patients 4 have shown overall hematologic improvement (HI) with 3 showing trilineage improvement. Two patients had stable disease.
In conclusion, the curcumin/gingerol combination is well tolerated and potentially beneficial for early stage MDS patients who are not transfusion dependent.


View this table:
[in this window]
[in a new window]

 
 




This Article
Services
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Raza, A.
Right arrow Articles by Galili, N.
PubMed
Right arrow Articles by Raza, A.
Right arrow Articles by Galili, N.